Piet L. C. M. Van Riel

Piet L. C. M. Van Riel's AcademicInfluence.com Rankings

Philosophy

#8144

World Rank

#11470

Historical Rank

Logic

#5174

World Rank

#6550

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Piet L. C. M. Van Riel's Degrees

PhD Medicine University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Piet L. C. M. Van Riel Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Piet L. C. M. Van Riel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs (2010) (4048)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010) (2474)
Genetics of rheumatoid arthritis contributes to biology and drug discovery (2013) (1877)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update (2013) (1711)
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. (2003) (930)
The Disease Activity Score and the EULAR response criteria. (2005) (744)
Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate (2008) (656)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed (2004) (630)
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. (2007) (540)
Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. (2004) (473)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 (2006) (464)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 (2011) (464)
Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid Arthritis (1993) (422)
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology (2002) (408)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis (2008) (397)
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis (2010) (358)
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. (2014) (339)
Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. (2004) (339)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. (2008) (318)
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. (1994) (309)
Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study (2005) (269)
The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. (2004) (265)
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. (1997) (250)
Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis (2014) (246)
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. (1999) (230)
Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis (2004) (224)
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries (2011) (218)
Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. (2010) (216)
Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. (2005) (207)
A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. (2010) (204)
Minimal disease activity for rheumatoid arthritis: a preliminary definition. (2005) (203)
Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis (1999) (203)
A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. (2002) (199)
Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial (2005) (193)
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice (2007) (184)
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors (2006) (180)
Fatigue as experienced by patients with rheumatoid arthritis (RA): a qualitative study. (2008) (175)
Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study (2003) (173)
The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis (2008) (172)
Cognitive–behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions (2006) (170)
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis (2017) (169)
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis (2007) (163)
Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis (2007) (163)
The Disease Activity Score and the EULAR response criteria. (2009) (162)
Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy (2011) (158)
Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis (2013) (152)
Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study (2006) (151)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 (2013) (145)
Persistent severe fatigue in patients with rheumatoid arthritis. (2007) (144)
Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome. (2010) (144)
The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. (2004) (144)
Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. (1999) (143)
Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. (2005) (139)
The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. (2016) (139)
Common and different genetic background for rheumatoid arthritis and coeliac disease. (2009) (138)
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry (2012) (137)
Tailored cognitive–behavioral therapy and exercise training for high‐risk patients with fibromyalgia (2010) (136)
Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs (2009) (135)
The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data (2007) (128)
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis (2003) (127)
The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients (2014) (124)
Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. (2011) (119)
Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. (2003) (119)
Burden of disease in treated rheumatoid arthritis patients: going beyond the joint. (2014) (118)
Association of STAT4 with rheumatoid arthritis: a replication study in three European populations. (2008) (118)
Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients (2008) (115)
EULAR definition of difficult-to-treat rheumatoid arthritis (2020) (114)
Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. (2016) (112)
Right ventricle Tei-index: a tool to increase the accuracy of non-invasive detection of pulmonary arterial hypertension in connective tissue diseases. (2007) (111)
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. (2011) (111)
Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study (2012) (108)
Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study (2012) (107)
Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene (2007) (107)
Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade (2010) (105)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 (2007) (103)
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis (2012) (101)
Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms (2015) (99)
Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries (2017) (98)
Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. (2002) (94)
Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA) (2008) (94)
Rituximab treatment in patients with refractory inflammatory myopathies. (2011) (92)
Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. (2012) (87)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 (2009) (87)
Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study (2007) (86)
DAS remission cut points. (2006) (86)
How does one assess early rheumatoid arthritis in daily clinical practice? (2001) (82)
Tumour necrosis factor α −308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis (2009) (80)
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe (2009) (80)
The PTPN22 R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian case-control samples. (2011) (80)
Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis (2009) (78)
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort (2012) (78)
Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis (2008) (78)
How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis (2014) (77)
A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides (2013) (77)
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration (2011) (75)
Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. (2003) (75)
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study (2015) (75)
Association of variation in Fcγ receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples (2010) (74)
TLR2 Promotes Th2/Th17 Responses via TLR4 and TLR7/8 by Abrogating the Type I IFN Amplification Loop1 (2009) (74)
Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. (2009) (73)
Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care (2009) (72)
Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open‐Label Randomized Controlled Trial (2016) (72)
Disease activity measures for rheumatoid arthritis. (2007) (72)
Minimal clinically important difference module: summary, recommendations, and research agenda. (2001) (71)
Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study (2017) (71)
The functional variant of the inhibitory Fcgamma receptor IIb (CD32B) is associated with the rate of radiologic joint damage and dendritic cell function in rheumatoid arthritis. (2006) (71)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 (2008) (70)
Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis (2007) (70)
Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. (2004) (69)
Clinical outcome measures in rheumatoid arthritis (2000) (69)
Correction: Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy (2011) (67)
Validation Study of Existing Gene Expression Signatures for Anti-TNF Treatment in Patients with Rheumatoid Arthritis (2012) (66)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations (2008) (65)
The Nijmegen inception cohort of early rheumatoid arthritis. (2004) (65)
Fatigue in patients with rheumatoid arthritis: what is known and what is needed. (2008) (63)
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry (2013) (63)
Consensus Dutch Health Assessment Questionnaire (2006) (63)
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study (2008) (62)
Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment (2007) (62)
Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals (2012) (61)
When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? (2004) (60)
Time to achieve remission determines time to be in remission (2010) (60)
Does stress affect the joints? Daily stressors, stress vulnerability, immune and HPA axis activity, and short-term disease and symptom fluctuations in rheumatoid arthritis (2013) (60)
Factors that influence rheumatologists' decisions to escalate care in rheumatoid arthritis: Results from a choice‐based conjoint analysis (2010) (60)
Experimental stress in inflammatory rheumatic diseases: a review of psychophysiological stress responses (2010) (59)
Inhibition of TNFα during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNFα blockade in rheumatoid arthritis (2004) (59)
Outcome measures in inflammatory rheumatic diseases (2009) (56)
The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion. (2012) (56)
Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis (2013) (56)
The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. (2012) (55)
Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. (2011) (54)
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial (2015) (54)
Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. (2013) (54)
Are patients' judgments of health status really different from the general population? (2011) (54)
Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. (2007) (53)
Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis (2008) (53)
The interferon regulatory factor 5 gene confers susceptibility to rheumatoid arthritis and influences its erosive phenotype (2010) (52)
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools (2016) (52)
Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice (2014) (51)
A tailored-guided internet-based cognitive-behavioral intervention for patients with rheumatoid arthritis as an adjunct to standard rheumatological care: results of a randomized controlled trial (2017) (51)
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis (2018) (50)
Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology (2014) (50)
The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis (2009) (50)
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. (2011) (49)
Novel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, Toll-like receptors and rheumatoid synovial fluid (2006) (48)
Development of type 1 diabetes in a patient treated with anti-TNF-α therapy for active rheumatoid arthritis (2009) (48)
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. (2005) (46)
Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. (2003) (45)
Enhanced interleukin‐10 production by dendritic cells upon stimulation with Toll‐like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion (2009) (45)
Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial (2007) (45)
The Inhibitory FcγIIb Receptor Dampens TLR4-Mediated Immune Responses and Is Selectively Up-regulated on Dendritic Cells from Rheumatoid Arthritis Patients with Quiescent Disease1 (2009) (44)
Fatigue in knee and hip osteoarthritis: the role of pain and physical function. (2011) (44)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 (2006) (44)
Developing an effective treatment algorithm for rheumatoid arthritis. (2012) (43)
Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. (2015) (43)
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. (2013) (43)
Development of quality indicators for monitoring of the disease course in rheumatoid arthritis (2009) (42)
Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis (2017) (42)
HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. (2008) (41)
The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries (2015) (40)
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study (2011) (40)
Gene expression profiling in rheumatoid arthritis: current concepts and future directions (2008) (40)
Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis (2016) (40)
Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. (2007) (40)
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (2016) (40)
Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. (2012) (39)
DAS28: a useful instrument to monitor infliximab treatment in patients with rheumatoid arthritis (2005) (39)
Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma (2007) (39)
Tailored cognitive-behavioral therapy for fibromyalgia: two case studies. (2008) (38)
MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. (2006) (38)
MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. (2003) (37)
Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry (2010) (37)
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis (2021) (36)
MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. (2003) (35)
Fatigue in patients with rheumatoid arthritis: British and Dutch nurses' knowledge, attitudes and management. (2009) (35)
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. (2005) (35)
High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study (2012) (35)
Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. (2003) (35)
Psychophysiological Responses to Stress after Stress Management Training in Patients with Rheumatoid Arthritis (2011) (34)
Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study (2009) (34)
Dendritic cells, Fcγ receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis (2005) (34)
Association of the X-Chromosomal Genes TIMP1 and IL9R with Rheumatoid Arthritis (2009) (33)
Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation (2011) (33)
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study (2012) (33)
How to improve DAS28 use in daily clinical practice?--a pilot study of a nurse-led intervention. (2010) (32)
Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome (2010) (31)
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. (2013) (31)
Calibration of the PROMIS Physical Function Item Bank in Dutch Patients with Rheumatoid Arthritis (2014) (31)
The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study (2007) (30)
Comment on the use of self-reporting instruments to assess patients with rheumatoid arthritis: the longitudinal association between the DAS28 and the VAS general health. (2006) (30)
Tailored cognitive–behavioural therapy and exercise training improves the physical fitness of patients with fibromyalgia (2011) (30)
Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds (2000) (29)
Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis (2007) (29)
Comparison of internal and external responsiveness of the generic Medical Outcome Study Short Form-36 (SF-36) with disease-specific measures in rheumatoid arthritis. (2008) (29)
Effectiveness of a Third Tumor Necrosis Factor-α-blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis (2011) (28)
Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis (2014) (28)
Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. (2007) (28)
Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study (2015) (28)
Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data (2008) (27)
Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis (2004) (27)
Risk factors for longer term psychological distress in well-functioning fibromyalgia patients: a prospective study into prognostic factors. (2010) (27)
The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial (2011) (27)
Identification of novel genetic markers associated with the clinical phenotypes of systemic sclerosis through a genome wide association strategy (2010) (26)
Should We Redefine Treatment Targets in Rheumatoid Arthritis? Low Disease Activity Is Sufficiently Strict for Patients Who Are Anticitrullinated Protein Antibody-negative (2013) (26)
Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? (2005) (25)
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. (2015) (25)
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry (2016) (25)
Functional consequences of DECTIN-1 early stop codon polymorphism Y238X in rheumatoid arthritis (2010) (25)
Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. (2005) (24)
Immune responses to stress after stress management training in patients with rheumatoid arthritis (2013) (24)
Multiplex Screening of 22 Single-Nucleotide Polymorphisms in 7 Toll-like Receptors: An Association Study in Rheumatoid Arthritis (2010) (24)
Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry (2016) (24)
Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. (2009) (24)
Interchangeability of 28-joint disease activity scores using the erythrocyte sedimentation rate or the C-reactive protein as inflammatory marker (2014) (23)
Immune responses to stress in rheumatoid arthritis and psoriasis. (2014) (23)
Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. (2006) (23)
Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis (2008) (23)
Development and evaluation of a crosswalk between the SF-36 physical functioning scale and Health Assessment Questionnaire disability index in rheumatoid arthritis (2013) (23)
The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice? (2002) (23)
Achieving tight control in rheumatoid arthritis. (2011) (22)
Evidence for PTPN22 R620W Polymorphism As the Sole Common Risk Variant for Rheumatoid Arthritis in the 1p13.2 Region (2011) (22)
Psychometric properties of the Rheumatoid Arthritis Disease Activity Index (RADAI) in a cohort of consecutive Dutch patients with RA starting anti-tumour necrosis factor treatment (2007) (22)
Prevalence and predictors of health care use in patients with early hip or knee osteoarthritis: two-year follow-up data from the CHECK cohort. (2012) (22)
Meta-analysis identified the TNFA -308G > A promoter polymorphism as a risk factor for disease severity in patients with rheumatoid arthritis (2012) (21)
Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis (2008) (21)
Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. (2011) (21)
IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis (2017) (21)
Patient Self-Management and Tracking: A European Experience. (2019) (21)
Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors (2017) (20)
Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients (2019) (20)
Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha. (2008) (20)
Identification of the oxidative stress-related gene MSRA as a rheumatoid arthritis susceptibility locus by genome-wide pathway analysis. (2010) (20)
Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: a prospective drug survival study. (1991) (20)
Imaging in rheumatoid arthritis: results of group discussions. (1999) (20)
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. (2003) (20)
Assessment of Fatigue in Rheumatoid Arthritis: A Psychometric Comparison of Single-item, Multiitem, and Multidimensional Measures (2015) (20)
The relationship between change in subjective outcome and change in disease: a potential paradox (2010) (20)
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies (2008) (19)
Comparative responsiveness of the EuroQol‐5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: Results of the Dutch Rheumatoid Arthritis Monitoring registry (2012) (19)
Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care (2017) (19)
Fatigue communication at the out-patient clinic of Rheumatology. (2009) (19)
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor α-neutralising treatments in rheumatoid arthritis (2007) (19)
Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers (2008) (18)
Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare (2015) (18)
The functional variant (Asp299gly) of toll-like receptor 4 (TLR4) influences TLR4-mediated cytokine production in rheumatoid arthritis. (2008) (18)
Telemedicine in the management of rheumatoid arthritis: maintaining disease control with less health-care utilization (2021) (18)
Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry (2016) (18)
Confirmatory factor analysis of the Arthritis Impact Measurement Scales 2 short form in patients with rheumatoid arthritis. (2008) (17)
Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis. (2006) (17)
Fc gamma receptor mediated modulation of dendritic cells as a potential strategy in the battle against rheumatoid arthritis. (2006) (17)
Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis. (2007) (17)
Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment (2018) (17)
Exploring the public health impact of an intensive exercise program for patients with rheumatoid arthritis: A dissemination and implementation study (2010) (17)
Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs. (2009) (16)
Established rheumatoid arthritis: clinical assessments. (2007) (16)
Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It (2016) (16)
Quality in rheumatoid arthritis care. (2015) (15)
Design and analysis of a randomized controlled trial testing the effects of clinical decision support on the management of rheumatoid arthritis. (2004) (15)
A patient's perspective on multidisciplinary treatment gain for fibromyalgia: an indicator for pre-post treatment effects? (2009) (15)
Management of established rheumatoid arthritis with an emphasis on pharmacotherapy. (2007) (15)
The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). (2014) (15)
Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related) (2017) (14)
Predictors of satisfactory improvements in pain for patients with early rheumatoid arthritis in a treat-to-target study. (2015) (14)
Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. (1999) (14)
Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis. (2013) (14)
Are better endpoints and better design of clinical trials needed? (2004) (13)
Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis (2011) (13)
A Replication Study of the Association between Rheumatoid Arthritis and Deletion of the Late Cornified Envelope Genes LCE3B and LCE3C (2012) (13)
Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model (2015) (13)
Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry (2015) (12)
Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice. (2015) (12)
A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis. (2016) (12)
Treatment outcomes of a Numeric Rating Scale (NRS)-guided pharmacological pain management strategy in symptomatic knee and hip osteoarthritis in daily clinical practice. (2012) (12)
Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis (2018) (12)
AB0475 The influence of switching from etanercept originator to its biosimilar on effectiveness and and the impact of shared decision making on retention and withdrawal rates (2018) (11)
Ups and downs in the treatment strategies of rheumatoid arthritis. (2011) (11)
To be in remission or not: is that the question? (2005) (11)
Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit (2021) (11)
Patients’ experiences regarding self-monitoring of the disease course: an observational pilot study in patients with inflammatory rheumatic diseases at a rheumatology outpatient clinic in The Netherlands (2020) (11)
Combination of second-line antirheumatic drugs. (1997) (11)
Measuring the Therapeutic Relationship in Internet-Based Interventions (2015) (10)
Mucocutaneous reactions to gold: a prospective study of 74 patients with rheumatoid arthritis. (1994) (10)
Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. (2008) (10)
Determinants Associated with Work Participation in Patients with Established Rheumatoid Arthritis Taking Tumor Necrosis Factor Inhibitors (2014) (9)
Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity (2018) (9)
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity (2018) (9)
The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions. (2015) (9)
One-year results after transitioning from etanercept originator to biosimilar in a setting promoting shared decision-making in rheumatology (2020) (8)
Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models (2020) (8)
Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? (2009) (8)
Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment. (2016) (8)
Serum Samples That Have Been Stored Long-Term (>10 Years) Can Be Used as a Suitable Data Source for Developing Cardiovascular Risk Prediction Models in Large Observational Rheumatoid Arthritis Cohorts (2014) (8)
The influence of patient perceptions of disease on medication intensification in daily practice. (2016) (8)
Tailored Therapist-guided Internet-based Cognitive-behavioural Treatment for Psoriasis and Rheumatoid Arthritis: Two Case Reports. (2018) (7)
[Practice guideline 'Diagnosis and treatment of rheumatoid arthritis']. (2009) (7)
Effect of significant weight loss on disease activity: reason to implement this non-pharmaceutical intervention in daily clinical practice (2021) (7)
Exercise participation has increased in patients with Rheumatoid Arthritis: A cross-sectional comparison between two Dutch RA cohorts (2018) (7)
What does the clinician need to improve patient care in systemic sclerosis? (2007) (7)
Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era. (2018) (7)
Targeted therapies: summary clinical trials working group (2006) (6)
The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey. (2017) (6)
Tailored, Therapist-Guided Internet-Based Cognitive Behavioral Therapy Compared to Care as Usual for Patients With Rheumatoid Arthritis: Economic Evaluation of a Randomized Controlled Trial (2018) (6)
Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment (2019) (6)
Leflunomide improves the clinical response in patients with active rheumatoid arthritis treated with methotrexate. (2003) (6)
OP0181 Ultrasonography as Predictor for Flare in Rheumatoid Arthritis Patients with Low Disease Activity: Nine Month Results from Poet-Us-Study (2015) (6)
A Simplified Baseline Prediction Model for Joint Damage Progression in Rheumatoid Arthritis: A Step toward Personalized Medicine (2015) (5)
The use of captopril in rheumatoid arthritis: combining treatment targets! (2013) (5)
Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration (2012) (5)
Evaluation of disease activity assessments in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy: analyses of abatacept clinical trial data. (2010) (5)
Does Etanercept Biosimilar Prescription in a Rheumatology Center Bend the Medication Cost Curve? (2020) (5)
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis-results from 19 countries. (2021) (5)
Evaluating quality of care in rheumatoid arthritis: the patient perspective (2017) (4)
No evidence of association of the KLF12 gene with rheumatoid arthritis in Spanish and Dutch cohorts and a meta-analysis of published data. (2011) (4)
A pilot study of CXCL8 levels in crystal proven gout patients during allopurinol treatment and their association with cardiovascular disease. (2017) (4)
Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis (2018) (4)
Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis (2017) (4)
Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment (2004) (4)
Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy (2017) (4)
Strategies for implementation of guideline recommended cardiovascular risk management for patients with rheumatoid arthritis: results from a questionnaire survey of expert rheumatology centers (2020) (4)
The Functional Polymorphism 844 A>G in FcαRI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility (2011) (4)
Biosimilars in the management of chronic inflammatory diseases: The Dutch experience (2019) (3)
FRI0169 Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis – Results from an International European Collaboration (2015) (3)
Human leucocyte antigen phenotypes and gold-induced remissions in patients with rheumatoid arthritis. (1995) (3)
The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists (2020) (3)
Can CXCL16 be linked to coronary vascular disease? Comment on the article by Sheikine et al. (2006) (3)
Bridging the gap between aggregate data and individual patient management: A Bayesian approach (2011) (3)
Correction: Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy (2011) (3)
Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et al. (2007) (3)
Nephrotic syndrome associated with anti-tumor necrosis factor alpha therapy in a patient with rheumatoid arthritis: comment on the article by Charles et al. (2002) (3)
OP0257 Rheumatoid Arthritis-Specific Cardiovascular Risk Calculators Are Not Superior To Risk Calculators Established for The General Population: A Validation Analysis in A Cohort of RA Patients from 7 Countries (2016) (2)
FRI0328 Fixed versus On-Flare Retreatment with Rituximab in RA – Results from the Cererra Collaboration (2014) (2)
Functional variants of the macrophage migration inhibitory factor do not infer risk of cardiovascular disease in rheumatoid arthritis (2007) (2)
OP0181 Prediction of Flare after Stopping TNF-Inhibitor by Baseline Ultrasonography and Patient Characteristics in Rheumatoid Arthritis Patients with Low Disease Activity: 12-Month Results (2016) (2)
Co-Design of a Disease Activity Based Self-Management Approach for Patients with Rheumatoid Arthritis (2021) (2)
OP0069 Significantly Better Results for TNFI Combination Therapy with MTX Than TNFI Mono- and Combination Without MTX Therapy in Patients with RA: Results from the Dream Registry (2013) (2)
THU0086 Seropositivity and response to RTX: Data from the cererra collaboration (2013) (2)
A different perspective: Inflammatory rheumatic diseases and other organs. (2016) (1)
Two parallel short forms to measure disease- and treatment-associated knowledge in rheumatoid arthritis: application of item response theory (2020) (1)
Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration (2016) (1)
FRI0017 How Age, Gender and Body Mass Index Affect the Erythrocyte Sedimentation Rate and the C-Reactive Protein in Early Rheumatoid Arthritis (2014) (1)
SAT0481 Are TNF blocking agents associated with changes in work participation in patients with RA? (2013) (1)
Patient involvement in rheumatoid arthritis care to improve disease activity-based management in daily practice: A randomized controlled trial. (2021) (1)
Macrophage dysfunction in Psoriatic Arthritis (2011) (1)
SAT0036 Retention of Tocilizumab Therapy: A Comparison between Tocilizumab in Monotherapy and in Combination with DMARDS Based on the Tocerra Collaboration (2014) (1)
THU0592 Longitudinal Measurement of Fatigue in Rheumatoid Arthritis: Which Factors Predict Fatigue? (2013) (1)
Disease activity–based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade (2020) (1)
Chronic polyarthritis due to Pseudomonas aeruginosa. (1993) (1)
SAT0119 The relationship between inflammation and joint damage in rheumatoid arthritis is dependent on anti-CCP status (2013) (1)
THU0263 Factors Associated with Fatigue in Patients with Rheumatoid Arthritis: A Multidimensional “Path Analysis” Model (2014) (1)
Rheumatoid arthritis: understanding joint damage and physical disability in RA. (2011) (1)
SAT0157 Randomized Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients with Stable Remission or Low Disease Activity in the Netherlands (2015) (1)
β2 integrins control the proinflammatory phenotype of type 1 macrophages and dendritic cells (2010) (0)
THU0590 The Patient-Therapist Relationship as An Indicator for Treatment Success in E-Health Treatments for Patients with Rheumatoid Arthritis and Psorias (2013) (0)
THU0123 DIABETES MELLITUS AND CARDIOVASCULAR RISK MANAGEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A LARGE INTERNATIONAL AUDIT (2020) (0)
Excellence in Rheumatology 2012 25–28 January Madrid (2012) (0)
SAT0604 Dutch Quality Registry Rheumatoid Arthritis: Development of Quality Indicators (2016) (0)
FRI0345 Tapering MTX in Patients with RA Using TNFI Treatment is Possible (2015) (0)
THU0168 How Low Should You Go? Towards Personalized Treatment Targets for Disease Activity in RA (2013) (0)
SAT0052 Comparison of Physical Activity and Level of Fatigue Among Patients with Rheumatoid Arthritis and the General Dutch Population (2015) (0)
AB0776 Muscle ultrasonography: a potential new diagnostic tool for inflammatory myopathies (2018) (0)
ETANERCEPT (ENBREL®) PLUS METHOTREXATE OR ETANERCEPT ALONE IMPROVES ACR RESPONSES IN RHEUMATOID ARTHRITIS PATIENTS INADEQUATELY RESPONDING TO METHOTREXATE: CLINICAL EFFICACY AND SAFETY RESULTS FROM ADORE (EUROPEAN STUDY): 143 (2006) (0)
Reply (2011) (0)
AB0429 The association between psychosocial factors and physical activity measured by actigraphy in patient with rheumatoid arthritis (2013) (0)
THU0478 Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors (2014) (0)
FRI0696 THE NEXT STEP; MOVING TOWARDS A MORE PHYSICALLY ACTIVE RHEUMATOLOGY POPULATION (2019) (0)
AB0428 The association between physical activity measured by actigraphy and fatigue in patient with rheumatoid arthritis (2013) (0)
Measurement bias in different versions of the Dutch Health Assessment Questionnaire Disability Index (2013) (0)
SAT0091 SURVEY OF CARDIOVASCULAR DISEASE AND RISK FACTOR MANAGEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ACROSS 5 WORLD REGIONS: RESULTS FROM THE SURF-RA (2020) (0)
FRI0427 Getting a grip on tight control: Predictors of medication escalation in RA in practice (2013) (0)
FRI0198 The risk of chronic q fever in rheumatoid arthritis patients with and without anti-tnf therapy (2013) (0)
Are prognostic factors in rheumatoid arthritis of any use in daily clinical practice? (2002) (0)
SAT0683 NORMATIVE DATA FOR THE DISEASE AND TREATMENT ASSOCIATED KNOWLEDGE SCORE (DATAK-RA) IN PATIENTS WITH RHEUMATOID ARTHRITIS (2019) (0)
Oral Anticoagulant Treatment in Atrial Fibrillation in Patients with Rheumatoid Arthritis - Results of an International Audit (2022) (0)
OP0159-HPR Reumanet bernhoven: introduction and evaluation of an online self-management tool and personal health environment for patients with rheumatoid arthritis(RA) (2018) (0)
AB1301 Cardiovascular risk age and vascular age estimations in predicting cardiovascular events in rheumatoid arthritis patients (2018) (0)
Unregulated prescribing of anti-tumour necrosis factor agents does not mean inappropriate prescribing (2009) (0)
THU0247 Spa-net: a disease-specific integrated ehealth system and quality registry for spondyloarthritis in daily practice in the netherlands (2018) (0)
AB1435-HPR The contribution of assessing foot joints in early rheumatoid arthritis patients: Insights from item response theory (2013) (0)
AB1028 Development and Validation of A Patient Questionnaire on Rheumatoid Arthritis Disease Related Knowledge in The Treat To Target Era: Preliminary Results (2016) (0)
OP0028 Efficacy of different doses of rituximab for the treatment of RA: Data from the cererra collaboration (2013) (0)
Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial (2019) (0)
Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit (2022) (0)
SAT0229 Effectiveness of Repeated Courses of Rituximab in RA – Results from the Cererra Collaboration (2014) (0)
FRI0565 Influence of Route of Administration/drug Formulation and Other Factors on Compliance with Treatment in Rheumatoid Arthritis and Dyslipidaemia (2016) (0)
THU0196 Efficacy of and predisposing factors for response to leflunomide (lef) in patients with rheumatoid arthritis (ra) (2001) (0)
A Clinical Audit of Cardiovascular Risk Factors and Disease in Patients with Rheumatoid Arthritis - SURF-RA (2022) (0)
Dr. van Lieshout, et al reply (2009) (0)
SAT0603 Evaluating Quality of Care in Rheumatoid Arthritis: Patients Perspective (2016) (0)
SAT0253 Cost-Effectiveness of Abatacept, Rituximab or A TNFI after Failure of the First TNFI Treatment in RA: Results of A Multi-Centered Pragmatic RCT in the DREAM Registry (2014) (0)
OP0116 Cost-effectiveness and cost-utility analysis of treat-to-target versus usual care in early rheumatoid arthritis: Results of the dream registry (2013) (0)
AB1274 The effect of implementing an online patient health record aiming to promote patient participation in rheumatoid arthritis patients on the use of disease-modifying antirheumatic drugs and outcome in daily clinical practice (2018) (0)
Prednisone in Managing Rheumatoid Arthritis (1994) (0)
THU0118 General Applicability of a New Treat-to-Target Treatment Strategy in Dutch Patients with Early Rheumatoid Arthritis: Results from the Dream Remission induction Cohort II (2015) (0)
FRI0336 Effectiveness of Abatacept, Rituximab or A TNFI after Failure of the First Tnfi: Results of A Multi-Centered Pragmatic Rct (2014) (0)
FRI0625 Different strategies to implement the eular guideline for cardiovascular risk management in daily practice (2018) (0)
THU0634 Sex Differences in Cardiovascular Risk Factors and Event Rates in Patients with Rheumatoid Arthritis - Data from 13 Rheumatology Centers (2016) (0)
SAT0729-HPR First experiences with online remote monitoring in patients with inflammatory rheumatic diseases (2018) (0)
SAT0730-HPR Development of psychometrically equivalent short forms to measure disease and treatment associated knowledge in rheumatoid arthritis: application of item response theory (IRT) (2018) (0)
THU0729-HPR Patient with rheumatoid arthritis are still not sufficiently physical active. time for a personalised physical activity programme! (2018) (0)
AB1105 Epidemiological Assessment of Baseline Characteristics of the Abatacept-Treated Patients in Select Real-World Rheumatoid Arthritis Data Sources (2014) (0)
FRI0109 Predicting cardiovascular disease in rheumatoid arthritis: The effect of long-term storage on measured cholesterol levels in frozen serum samples (2013) (0)
OP0343-HPR An economic evaluation of a tailored guided internet-based cognitive behavioural intervention for patients with rheumatoid arthritisas an addition to usual care (2018) (0)

This paper list is powered by the following services:

Piet L. C. M. Van Riel's Academic­Influence.com Rankings

Piet L. C. M. Van Riel's Degrees

Why Is Piet L. C. M. Van Riel Influential?

Piet L. C. M. Van Riel's Published Works

Published Works

Piet L. C. M. Van Riel's AcademicInfluence.com Rankings